Literature DB >> 22321468

Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses.

Pranav Periyalwar1, Srinivasan Dasarathy.   

Abstract

Malnutrition is the most common, reversible complication of cirrhosis that adversely affects survival, response to other complications, and quality of life. Sarcopenia, or loss of skeletal muscle mass, and loss of adipose tissue and altered substrate use as a source of energy are the 2 major components of malnutrition in cirrhosis. Current therapies include high protein supplementation especially as a late evening snack. Exercise protocols have the potential of aggravating hyperammonemia and portal hypertension. Recent advances in understanding the molecular regulation of muscle mass has helped identify potential novel therapeutic targets including myostatin antagonists, and mTOR resistance.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321468      PMCID: PMC4383161          DOI: 10.1016/j.cld.2011.12.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  189 in total

1.  Myostatin induces autophagy in skeletal muscle in vitro.

Authors:  Jen Y Lee; Nicholas S Hopkinson; Paul R Kemp
Journal:  Biochem Biophys Res Commun       Date:  2011-11-02       Impact factor: 3.575

2.  Factors associated with nutritional status in liver transplant patients who survived the first year after transplantation.

Authors:  Luciana de Carvalho; Edison Roberto Parise; Didier Samuel
Journal:  J Gastroenterol Hepatol       Date:  2009-11-19       Impact factor: 4.029

Review 3.  Adjuvant nutrition management of patients with liver failure, including transplant.

Authors:  Andrew J Kerwin; Michael S Nussbaum
Journal:  Surg Clin North Am       Date:  2011-04-29       Impact factor: 2.741

4.  Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety.

Authors:  A Donaghy; R Ross; C Wicks; S C Hughes; J Holly; A Gimson; R Williams
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

Review 5.  Molecular mechanisms and treatment options for muscle wasting diseases.

Authors:  Markus A Rüegg; David J Glass
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

6.  ESPEN Guidelines on Enteral Nutrition: Liver disease.

Authors:  M Plauth; E Cabré; O Riggio; M Assis-Camilo; M Pirlich; J Kondrup; P Ferenci; E Holm; S Vom Dahl; M J Müller; W Nolte
Journal:  Clin Nutr       Date:  2006-05-16       Impact factor: 7.324

7.  Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients.

Authors:  Federica Moscucci; Silvia Nardelli; Ilaria Pentassuglio; Chiara Pasquale; Lorenzo Ridola; Manuela Merli; Oliviero Riggio
Journal:  Liver Int       Date:  2011-08-15       Impact factor: 5.828

8.  A comparison of skinfold anthropometry and bioelectrical impedance analysis for measuring percentage body fat in patients with cirrhosis.

Authors:  A M Madden; M Y Morgan
Journal:  J Hepatol       Date:  1994-11       Impact factor: 25.083

9.  Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt.

Authors:  Michael R Morissette; Stuart A Cook; Cattleya Buranasombati; Michael A Rosenberg; Anthony Rosenzweig
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-16       Impact factor: 4.249

10.  Treating cancer cachexia to treat cancer.

Authors:  Se-Jin Lee; David J Glass
Journal:  Skelet Muscle       Date:  2011-01-24       Impact factor: 4.912

View more
  83 in total

Review 1.  Changes in nutritional status after liver transplantation.

Authors:  Michela Giusto; Barbara Lattanzi; Vincenza Di Gregorio; Valerio Giannelli; Cristina Lucidi; Manuela Merli
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.

Authors:  Avinash Kumar; Gangarao Davuluri; Rafaella Nascimento E Silva; Marielle P K J Engelen; Gabrie A M Ten Have; Richard Prayson; Nicolaas E P Deutz; Srinivasan Dasarathy
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

3.  Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis.

Authors:  Elliot B Tapper; Daniel Finkelstein; Murray A Mittleman; Gail Piatkowski; Michelle Lai
Journal:  Hepatology       Date:  2015-04-28       Impact factor: 17.425

Review 4.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

5.  Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.

Authors:  Soichi Iritani; Kenji Imai; Koji Takai; Tatsunori Hanai; Takayasu Ideta; Tsuneyuki Miyazaki; Atsushi Suetsugu; Makoto Shiraki; Masahito Shimizu; Hisataka Moriwaki
Journal:  J Gastroenterol       Date:  2014-05-10       Impact factor: 7.527

6.  Exercise and physical activity in cirrhosis: opportunities or perils.

Authors:  Annette Bellar; Nicole Welch; Srinivasan Dasarathy
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

7.  Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.

Authors:  Manuela Merli; Michela Giusto; Cristina Lucidi; Valerio Giannelli; Ilaria Pentassuglio; Vincenza Di Gregorio; Barbara Lattanzi; Oliviero Riggio
Journal:  Metab Brain Dis       Date:  2012-12-07       Impact factor: 3.584

Review 8.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 9.  Branched-chain amino acids in liver diseases.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-30

Review 10.  Cause and management of muscle wasting in chronic liver disease.

Authors:  Srinivasan Dasarathy
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.